ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0976

Sarcopenia and All-Cause Mortality in US Adults with and Without Rheumatoid Arthritis

Qiping Xu and Xuanling Du, Mayo Clinic Health System, Mankato, MN

Meeting: ACR Convergence 2023

Keywords: Mortality, Muscle Biology, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (0965–0992) Epidemiology & Public Health Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Sarcopenia, which refers to the loss of muscle strength and mass, has been linked to adverse health outcomes. Although several systemic reviews have reported a high prevalence of sarcopenia in rheumatoid arthritis (RA) patients, the impact of sarcopenia on all-cause mortality in this population remains unclear. This study aims to determine the prevalence of sarcopenia in RA patients in a nationally representative cohort and evaluate its association with all-cause mortality in US adults with and without RA.

Methods: The study utilized data from the National Health and Nutrition Examination Survey (NHANES) 1999–2006, along with linked mortality data from the National Death Index up to the end of 2019. Sarcopenia was defined using the Foundation for the National Institutes of Health (FNIH) 2014 sarcopenia criteria: appendicular lean mass (ALM) divided by BMI (< 0.789 in men;< 0.512 in women). Rheumatoid arthritis cases were self-reported physician diagnoses. Population estimates, including prevalence and hazard ratio (HR), were generated by incorporating sample weights and cluster information. Four multivariate Cox proportional hazard models were constructed successively to produce adjusted HRs.

Results: The final cohort included 11909 participants aged 20 to 69, among which were 558 cases of rheumatoid arthritis (table 1).Figure 1 indicates that individuals with RA had a significantly higher age-standardized prevalence of sarcopenia compared to those without RA (11.3 % vs. 7.3 %). Notably, Hispanics had a significantly higher prevalence of sarcopenia than the rest of the population, with rates of 25.6% and 16.1% among individuals with RA and non-RA, respectively. Regarding survival analysis, the median follow-up time for RA and non-RA group was 17 and 16.8 years. After adjusting for age and sex, the unweighted Kaplan-Meier curve revealed that sarcopenic RA patients had the highest overall mortality (Figure 2a). Across all four adjusted Cox models, individuals with sarcopenia had a higher risk of mortality regardless of whether they had RA or not (Figure 2b). Despite all four Cox models providing higher estimates of HRs for sarcopenia in the RA group as compared to the non-RA group, the differences were not statistically significant given the overlapping confidence intervals.

Conclusion: In a nationally representative cohort, the study found a higher prevalence of sarcopenia in individuals with RA, and a significant increase in all-cause mortality associated with sarcopenia with or without RA.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: Q. Xu: None; X. Du: None.

To cite this abstract in AMA style:

Xu Q, Du X. Sarcopenia and All-Cause Mortality in US Adults with and Without Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/sarcopenia-and-all-cause-mortality-in-us-adults-with-and-without-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sarcopenia-and-all-cause-mortality-in-us-adults-with-and-without-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology